The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) and keeping the price ...

BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 9.81% of ...

Oppenheimer has recently resumed Gain Therapeutics Inc (GANX) stock to Outperform rating, as announced on August 14, 2024, according to Finviz. Earlier, on April 12, 2021, Oppenheimer had initiated ...

BETHESDA, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and ...

Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunctionBETHESDA, Md., March 05, 2024 (GLOBE NEWSWIRE) ...

BETHESDA, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

Foghorn Therapeutics Inc. (FHTX) shares rallied 9.5% in the last trading session to close at $9.72. This move can be attributable to notable volume with a higher number of shares being traded than in ...

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $67.10, demonstrating a +0.55% swing from the preceding day's closing price. The stock exceeded the S&P 500, which registered a ...

Summit Therapeutics stock rocketed again Thursday — adding onto an 85% gain this week — after raising $235 million in a private placement.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...